

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (Cancelled).

11. (Currently amended) A composition for the treatment of diseased, injured or abnormal bone, said composition comprising an effective amount of a growth factor, ~~and~~ hyaluronic acid[[,]] and excipients to maintain biological activity of said factor, said composition being sufficient to enhance bone growth rate and magnitude and having a viscosity ~~in the range of about 10 to 10⁶ cP~~ and biodegradability sufficient to persist upon application at a site of desired bone growth for a period of time sufficient to enhance said bone growth rate and magnitude.
12. (Original) A composition according to claim 11 wherein said viscosity is about 75,000 cP.
13. (Original) A composition according to claim 11 wherein said hyaluronic acid is uncrosslinked.
14. (Original) A composition according to claim 11 wherein said composition comprises 0.1 to 4% by weight of hyaluronic acid in solution.
15. (Original) A composition according to claim 11 wherein said growth factor comprises bFGF.
16. (Original) A composition according to claim 15 wherein said bFGF is present in said composition in a range of about 10⁻⁶ to 100 mg/ml of said composition.
17. (Currently amended) A method of treating diseased, injured or abnormal bone at a site of desired bone growth comprising the step of applying to said site a composition comprising an effective amount of a mixture of hyaluronic acid, ~~and~~ a growth factor and excipients to maintain biological activity of said factor, said composition being sufficient to enhance bone growth rate and magnitude and having a viscosity ~~in the range of about 10 to 10⁶ cP~~ and biodegradability sufficient to persist at said site for a period of time sufficient to enhance said bone growth rate and magnitude.
18. (Original) A method according to claim 17 wherein said viscosity is about 75,000 cP.
19. (Original) A method according to claim 17 wherein said hyaluronic acid is uncrosslinked.
20. (Original) A method according to claim 17 wherein said hyaluronic acid in said composition comprises about 0.1-4% by weight of said composition.

21. (Original) A method according to claim 17 wherein said growth factor comprises bFGF.
22. (Original) A method according to claim 21 wherein said bFGF is present in a range of about 10^{-6} to 100 mg/ml in said composition.